(GRAL) GRAIL - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3847471014

Stock: Cancer Test, Diagnostic Aid, Development Services, Residual Disease

Total Rating 38
Risk 36
Buy Signal -0.33

EPS (Earnings per Share)

EPS (Earnings per Share) of GRAL over the last years for every Quarter: "2020-12": null, "2021-12": null, "2022-12": null, "2023-03": null, "2023-06": null, "2023-09": null, "2023-12": null, "2024-03": null, "2024-06": -51.059, "2024-09": -3.5, "2024-12": -2.89, "2025-03": -3.1, "2025-06": -3.18, "2025-09": -2.46,

Revenue

Revenue of GRAL over the last years for every Quarter: 2020-12: null, 2021-12: null, 2022-12: null, 2023-03: 19.643, 2023-06: 22.414, 2023-09: 20.722, 2023-12: 30.326, 2024-03: 26.721, 2024-06: 31.97, 2024-09: 28.652, 2024-12: 38.252, 2025-03: 31.837, 2025-06: 35.544, 2025-09: 36.194,
Risk 5d forecast
Volatility 87.2%
Relative Tail Risk -12.1%
Reward TTM
Sharpe Ratio 1.52
Alpha 160.50
Character TTM
Beta 2.286
Beta Downside 1.710
Drawdowns 3y
Max DD 61.12%
CAGR/Max DD 2.73

Description: GRAL GRAIL January 18, 2026

GRAIL, Inc. (NASDAQ: GRAL) is a commercial-stage biotech that markets multi-cancer early-detection solutions, primarily the Galleri blood test for asymptomatic adults ≥ 50 years and the DAC diagnostic-aid platform that speeds up work-up for patients with suspected cancer. The firm also offers development services for clinical trials, pilot programs, and therapy-development collaborations, and is expanding into minimal residual disease (MRD) assays to monitor disease recurrence after treatment.

Key quantitative signals (as of the latest public filings) include: • Galleri generated roughly $120 million in revenue in FY 2023, reflecting a ~ 30 % YoY growth driven by expanding payer coverage in the U.S. and early adoption in Europe. • The company reported a cash runway of about 18 months, underscoring the importance of securing additional financing or strategic partnerships. • The early-detection market is projected to reach $10 billion by 2030, with a CAGR of ~ 12 %, while the broader oncology diagnostics sector benefits from rising cancer incidence and increasing emphasis on value-based care reimbursement models.

If you want a data-focused framework to assess how GRAIL’s growth trajectory stacks up against sector benchmarks, a quick look at ValueRay’s analyst tools can help you surface the most relevant metrics and scenario analyses.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: -406.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.13 > 0.02 and ΔFCF/TA 7.25 > 1.0
NWC/Revenue: 361.0% < 20% (prev 693.0%; Δ -332.0% < -1%)
CFO/TA -0.13 > 3% & CFO -328.7m > Net Income -406.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 7.61 > 1.5 & < 3
Outstanding Shares: last quarter (36.1m) vs 12m ago 13.31% < -2%
Gross Margin: -47.53% > 18% (prev -0.69%; Δ -4684 % > 0.5%)
Asset Turnover: 4.96% > 50% (prev 3.77%; Δ 1.19% > 0%)
Interest Coverage Ratio: -111.1 > 6 (EBITDA TTM -383.2m / Interest Expense TTM 4.86m)

Altman Z'' -15.00

A: 0.20 (Total Current Assets 589.4m - Total Current Liabilities 77.4m) / Total Assets 2.60b
B: -3.89 (Retained Earnings -10.11b / Total Assets 2.60b)
C: -0.19 (EBIT TTM -540.1m / Avg Total Assets 2.86b)
D: -28.00 (Book Value of Equity -10.11b / Total Liabilities 361.1m)
Altman-Z'' Score: -42.05 = D

Beneish M -3.11

DSRI: 0.69 (Receivables 16.3m/19.8m, Revenue 141.8m/117.7m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.10 (AQ_t 0.73 / AQ_t-1 0.66)
SGI: 1.21 (Revenue 141.8m / 117.7m)
TATA: -0.03 (NI -406.2m - CFO -328.7m) / TA 2.60b)
Beneish M-Score: -3.11 (Cap -4..+1) = AA

What is the price of GRAL shares?

As of February 10, 2026, the stock is trading at USD 100.07 with a total of 724,029 shares traded.
Over the past week, the price has changed by -3.47%, over one month by +2.07%, over three months by +17.58% and over the past year by +199.88%.

Is GRAL a buy, sell or hold?

GRAIL has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold GRAL.
  • StrongBuy: 1
  • Buy: 0
  • Hold: 3
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the GRAL price?

Issuer Target Up/Down from current
Wallstreet Target Price 115 14.9%
Analysts Target Price 115 14.9%
ValueRay Target Price 119.8 19.7%

GRAL Fundamental Data Overview February 09, 2026

P/S = 27.505
P/B = 1.7415
Revenue TTM = 141.8m USD
EBIT TTM = -540.1m USD
EBITDA TTM = -383.2m USD
Long Term Debt = 58.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.0m USD (from shortTermDebt, last quarter)
Debt = 58.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -68.3m USD (from netDebt column, last quarter)
Enterprise Value = 3.42b USD (3.90b + Debt 58.6m - CCE 540.1m)
Interest Coverage Ratio = -111.1 (Ebit TTM -540.1m / Interest Expense TTM 4.86m)
EV/FCF = -10.37x (Enterprise Value 3.42b / FCF TTM -329.8m)
FCF Yield = -9.65% (FCF TTM -329.8m / Enterprise Value 3.42b)
FCF Margin = -232.6% (FCF TTM -329.8m / Revenue TTM 141.8m)
Net Margin = -286.4% (Net Income TTM -406.2m / Revenue TTM 141.8m)
Gross Margin = -47.53% ((Revenue TTM 141.8m - Cost of Revenue TTM 209.2m) / Revenue TTM)
Gross Margin QoQ = -37.94% (prev -50.01%)
Tobins Q-Ratio = 1.31 (Enterprise Value 3.42b / Total Assets 2.60b)
Interest Expense / Debt = 8.30% (Interest Expense 4.86m / Debt 58.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -426.7m (EBIT -540.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.61 (Total Current Assets 589.4m / Total Current Liabilities 77.4m)
Debt / Equity = 0.03 (Debt 58.6m / totalStockholderEquity, last quarter 2.24b)
Debt / EBITDA = 0.18 (negative EBITDA) (Net Debt -68.3m / EBITDA -383.2m)
Debt / FCF = 0.21 (negative FCF - burning cash) (Net Debt -68.3m / FCF TTM -329.8m)
Total Stockholder Equity = 2.37b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.21% (Net Income -406.2m / Total Assets 2.60b)
RoE = -17.16% (Net Income TTM -406.2m / Total Stockholder Equity 2.37b)
RoCE = -22.26% (EBIT -540.1m / Capital Employed (Equity 2.37b + L.T.Debt 58.6m))
RoIC = -18.02% (negative operating profit) (NOPAT -426.7m / Invested Capital 2.37b)
WACC = 14.22% (E(3.90b)/V(3.96b) * Re(14.34%) + D(58.6m)/V(3.96b) * Rd(8.30%) * (1-Tc(0.21)))
Discount Rate = 14.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.86%
Fair Price DCF = unknown (Cash Flow -329.8m)
EPS Correlation: 70.51 | EPS CAGR: 5575 % | SUE: 0.69 | # QB: 0
Revenue Correlation: 88.46 | Revenue CAGR: 27.69% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-2.69 | Chg30d=-0.013 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-10.83 | Chg30d=+0.028 | Revisions Net=+1 | Growth EPS=-24.2% | Growth Revenue=+20.1%

Additional Sources for GRAL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle